Medical Clinic III for Oncology, Hematology, Immuno-Oncology, and Rheumatology, University Hospital Bonn, University of Bonn, Venusberg-Campus 1, 53127 Bonn, Germany.
Medical Clinic III for Oncology, Hematology, Immuno-Oncology, and Rheumatology, University Hospital Bonn, University of Bonn, Venusberg-Campus 1, 53127 Bonn, Germany.
Trends Cancer. 2023 Apr;9(4):309-325. doi: 10.1016/j.trecan.2022.12.007. Epub 2023 Jan 14.
T follicular helper (Tfh) cells provide essential help to B cells for effective antibody-mediated immune responses. Although the crucial function of these CD4 T cells in infection and vaccination is well established, their involvement in cancer is only beginning to emerge. Increased numbers of Tfh cells in Tfh cell-derived or B cell-associated malignancies are often associated with an unfavorable outcome, whereas in various solid organ tumor types of non-lymphocytic origin, their presence frequently coincides with a better prognosis. We discuss recent advances in understanding how Tfh cell crosstalk with B cells and CD8 T cells in secondary and tertiary lymphoid structures (TLS) enhances antitumor immunity, but may also exacerbate immune-related adverse events (irAEs) such as autoimmunity during immune checkpoint blockade (ICB) and cancer immunotherapy.
滤泡辅助性 T 细胞（Tfh）为 B 细胞提供了有效抗体介导免疫应答所必需的辅助。虽然这些 CD4 T 细胞在感染和疫苗接种中的关键作用已得到充分证实，但它们在癌症中的作用才刚刚开始显现。在 Tfh 细胞衍生或 B 细胞相关恶性肿瘤中，Tfh 细胞数量增加通常与不良预后相关，而在各种非淋巴细胞来源的实体器官肿瘤类型中，它们的存在常与更好的预后相关。我们讨论了理解 Tfh 细胞如何在次级和三级淋巴结构（TLS）中与 B 细胞和 CD8 T 细胞相互作用以增强抗肿瘤免疫的最新进展，但也可能加剧免疫相关不良事件（irAEs），如免疫检查点阻断（ICB）和癌症免疫治疗期间的自身免疫。
